Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Immune-related adverse events
•
Rheumatology
•
General Rheumatology
•
irae
How do you manage inflammatory arthritis that has occurred in the setting of treatment with Bruton tyrosine kinase (BTK) inhibitors?
Related Questions
What is your approach to management of drug induced oral and cutaneous lichen planus associated with TNF inhibitors?
In patients with history of anaphylaxis to a TNF inhibitor, are you comfortable trying an alternative TNF inhibitor?
How do you approach pre-conception counseling in males who are on medications for which there is limited or no data such as Jak inhibitors, apremilast, or belimumab?
What characteristics make a PMR patient a good candidate for sarilumab?
What treatment options do you recommend in a patient with idiopathic granulomatous mastitis that has not improved on steroids and methotrexate?
What is your approach to working up diarrhea in an immunocompromised patient?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
Would you feel comfortable adding benlysta to patient already taking both mycophenolate and tacrolimus (and hydroxychloroquine) who still has some evidence of active lupus nephritis?
Do oral NSAIDs and steroids have an effect on how you interpret synovial fluid leukocyte count?
How do you counsel and manage joint pain after isotretinoin treatment?
